The Center for Drug Discovery and Development (C3D) is an academic drug discovery team that aims to bridge the gap between fundamental cancer research and clinical trials. The C3D supports research teams by providing expertise, technology, and project management from target identification through preclinical development. Key services include screening, hit identification, medicinal chemistry, and preclinical testing to help validate targets and develop new cancer therapies.
The Center for Drug Discovery and Development (C3D) is an academic drug discovery team that aims to bridge the gap between fundamental cancer research and clinical trials. The C3D supports research teams by providing expertise, technology, and project management from target identification through preclinical development. Key services include screening, hit identification, medicinal chemistry, and preclinical testing to help validate targets and develop new cancer therapies.
The Center for Drug Discovery and Development (C3D) is an academic drug discovery team that aims to bridge the gap between fundamental cancer research and clinical trials. The C3D supports research teams by providing expertise, technology, and project management from target identification through preclinical development. Key services include screening, hit identification, medicinal chemistry, and preclinical testing to help validate targets and develop new cancer therapies.
The Center for Drug Discovery and Development (C3D) is an academic drug discovery team that aims to bridge the gap between fundamental cancer research and clinical trials. The C3D supports research teams by providing expertise, technology, and project management from target identification through preclinical development. Key services include screening, hit identification, medicinal chemistry, and preclinical testing to help validate targets and develop new cancer therapies.
Expertise The C3D, Center for Drug Discovery and Development is an academic drug discovery team created to fill the translational gap in oncolo- • Hit identification gy between fundamental research and patients. • Hit to Lead • Preclinical pharmacology profiling Target ID Target validation - Hit to lead - Candidate Clinic • Toxicology • Early-ADME • Medicinal chemistry Basic Assay Hit Lead Preclinical research development ID ID development • Non regulatory and regulatory preclinical development C3D
Instrumentation The aim of this platform is to • Automated liquid handling develop drug discovery programs (robotic platform TECAN EVO150) based on validated targets or bio- • Multi-technology microplate readers logical pathways identified by basic (96 – 384 wells) researchers. The mission of the • HPLC chains coupled to mass C3D is thus to provide research spectrometers teams with the means and tech- • HP D300 dispenser for titration nical support to identify, charac- (TECAN) terize and develop new therapies • Cell culture room (antibodies or small molecules). • HCS platform: operetta CLS Perkin The C3D focuses on the early Elmer stages of exploratory research, up until entry into clinical trials. Chemical librairies The C3D can support you: • To mature your project • Prestwick library, 1200 FDA approved • To validate your target compounds • To manage your drug discovery • Core library of 52 000 « drug like » program from hits identification compounds up to the clinic • Protein/protein inhibition library: • To decipher the mechanism 13 000 compounds of action of your compound • Natural like compounds: 1200 • To validate your biomarker • Kinase library (approved or under development drugs): 590 compounds Approaches: • New chemical entity development • Drug repurposing • Combo screening Project management
Selection of the project by the steering committee
Global strategy validation (C3D and project P.I.)
Access details Drug Discovery program initiation
We support your drug discovery project Program development in strong collaboration
at every developmental stage with the research team • Target validation • Screening • Hit to lead Core activities • Lead optimization • Biochemical assays Biology • Enzyme assays; protein-protein interaction; Binding assays Mention us in • Cell based assays (viability, gene reporter and apoptosis
your publications! assays)
• High Content Screening; phenotypic assays • Disease relevant assays To allow our platform to pursue its objectives, we need you to mention • Bio-layer interferometry our work in your publications as follows: Biophysics • NMR Centre for drug discovery and deve- lopment, Synergie Lyon Cancer, Lyon, • Compounds design and synthetic chemistry management France. Département de recherche Medical Chemistry • Structure Activity Relationship study translationnelle et d’innovations, • Activity, PK and Safety optimization based on biology Centre Léon Bérard, Lyon, France and ADMET
Stéphane Giraud – Scientific director and manager of the platform
›› PhD in biology with more than 12 years of experience
in multidisciplinary drug discovery projects undertaken in an international environment. ›› Over 10 years of experience in leading and managing of a research group. ›› Member of steering and strategic committees / ANR (National Research Agency) expert. ›› Business development, funding of research and Contacts innovation.
Stéphane Giraud CENTRE LÉON BERARD Cheney B building, 3rd floor 28, rue Laënnec - F-69008 Lyon Submission form and more infos: stephane.giraud@lyon.unicancer.fr www.cancer-research-lyon.com
